LYNPARZA (AstraZeneca)
(https://lynparza.com) 📸 Data Snapshot: May 31, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Authority is established through association with AstraZeneca and the inclusion of comprehensive Prescribing Information links. A minor gap exists in the schema identity, which is generic MedicalWebPage rather than more granular Drug or MedicalEntity schema. There are no named medical directors or specific clinical trial registration numbers (e.g., NCT numbers) immediately visible in the heading hierarchy or clean text.
The site avoids the standard performance disconnect by using highly qualified language: LYNPARZA may give you a different option or 7 out of 10 women may have recurrence. These are not bold marketing claims but statistically-driven medical assertions. The disconnect is minimal because pharmaceutical regulations prevent the brand from making unsubstantiated efficacy claims.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
[
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/",
"@type": "MedicalWebPage",
"name": "LYNPARZA",
"description": "Discover LYNPARZA—an oral, non-chemotherapy medication that may give you and your doctor a different option in the treatment of certain types of cancer."
},
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/",
"@type": "MedicalAudience",
"audienceType": "Patient",
"geographicArea": "For US consumers"
},
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/",
"@type": "Website",
"name": "Lynparza.com"
}
]
/ovarian-cancer/home.html
[
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/ovarian-cancer/home.html",
"@type": "MedicalWebPage",
"name": "Talk to your doctor about LYNPARZA for certain types of advanced or recurrent ovarian cancer.",
"description": "LYNPARZA is used as a maintenance therapy and can be taken alone or in combination with the medicine bevacizumab. Maintenance therapy is a treatment used after initial therapy has ended. It can help extend the time without cancer growing or returning."
},
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/ovarian-cancer/home.html",
"@type": "MedicalAudience",
"audienceType": "Patient",
"geographicArea": "For US consumers"
}
]
/patient-support.html
[
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/patient-support.html",
"@type": "MedicalWebPage",
"name": "Patient support",
"description": "Access resources that are designed to guide and support you during your treatment with LYNPARZA."
},
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/patient-support.html",
"@type": "MedicalAudience",
"audienceType": "Patient",
"geographicArea": "For US consumers"
}
]
/patient-support/my-lynparza-support-program.html
[
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/patient-support/my-lynparza-support-program.html",
"@type": "MedicalWebPage",
"name": "Education and support are available through MyLYNPARZA",
"description": "AstraZeneca developed this support program to be there for you and your loved ones during treatment with LYNPARZA. By signing up, you will receive advice and information about treatment"
},
{
"@context": "https://schema.org/",
"url": "https://www.lynparza.com/patient-support/my-lynparza-support-program.html",
"@type": "MedicalAudience",
"audienceType": "Patient",
"geographicArea": "For US consumers"
}
]
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 1 | 1 |
| /ovarian-cancer/home.html | 1 | 1 |
| /patient-support.html | 1 | 1 |
| /patient-support/my-lynparza-support-program.html | 2 | 1 |
This page presents a snapshot of public data from LYNPARZA (AstraZeneca), captured on May 31, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to LYNPARZA (AstraZeneca): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://lynparza.com to view the most current version of its content and see directly what this company is about and what it offers.